Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether calcium and vitamin D supplement can attenuate bone loss in HIV-infected-patients in Thailand who receive Tenofovir disoproxil fumarate.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mahidol University
• Treatments: Calcium; Calcium Carbonate; Calcium, Dietary; Efavirenz; Emtricitabine; Ergocalciferols; Lamivudine; Tenofovir; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• HIV-1-infected patients who start 3TC or FTC,TDF and EFV within 3 months before enrollment

• Age 18-50 years

Exclusion Criteria:

• CrCl <60mL/min/1.73 m2 ¶-

• CaCO3 supplement >500 mg/day or vitamin D supplement >800 IU/day

• Steroid used (equivalent to prednisolone> 5 mg/day more than 3 months )

• Osteoporosis treatment

• Serum Ca >10.5 g/dL

• History fragility fracture

• Pregnancy or breastfeeding

• Secondary amenorrhea

• Hyperthyroidism

• History of kidney stone

• Current active opportunistic infection